Advances in targeted nano-delivery of bevacizumab using nanoparticles: Current insights, innovations, and future perspectives

Abstract

This review article examines the transformative impact of bevacizumab (Avastin (R)) in cancer therapy over the past years, focusing on its future potential in oncological applications. Bevacizumab (BCZ), a humanized antibody targeting vascular endothelial growth factor (VEGF), has become a cornerstone in cancer treatment due to its angiogenesis inhibiting properties. The article highlights clinical advancements, such as the development of innovative formulations like cationic liposome conjugation and PEGylated nanoparticles, which enhance targeted delivery and reduce systemic toxicity, improving patient outcomes. The review also delves into the pharmacological challenges of BCZ, including its stability and handling of acidic and basic charge variants. Emerging research on anti-VEGF prolonged release systems and sophisticated drug delivery mechanisms, such as stimuli-responsive hydrogels and nanoparticles, underlines the shift towards personalized medicine. The review highlights the ongoing efforts and challenges in translating these nanomedicine innovations from bench to bedside, as evidenced by qualitative studies and clinical trials data. The review underscores the need for continued innovation and research in this area, emphasizing the pivotal role of BCZ in transforming cancer treatment paradigms.